Antibody-drug conjugates (ADCs), agents formed by linking cytotoxic payloads to monoclonal antibodies, hold immense potential to target a wide range of hematologic and solid tumors. Paul Ehrlich first proposed the concept for ADCs in 1904, shortly after antibodies were discovered. He imagined developing “magic bullets” composed of pathogen-targeted antibodies bound to toxins, which could eliminate a pathogen without harming healthy tissues. Subsequently, ADCs emerged from adapting Ehrlich’s ideas to the field of chemotherapy. If chemotherapies were linked to cancer-targeted antibodies, they could deliver treatment specifically to cancer cells, eradicating the cancer while sparing healthy tissue.
However, ADC development has since been complicated by several overarching challenges: (1) the lack of universal, cancer-specific antibodies; (2) the challenge of balancing an ADC’s tolerability and efficacy; (3) ADC provocation of a patient’s immune response; and (4) cancer developing mechanisms of resistance. At first, these challenges appeared to be nearly insurmountable. After the first ADC approval in 2000, only two additional ADCs received approval until 2017. Meanwhile, over 90 ADC candidates have failed during clinical trials.
Now, however, ADCs are experiencing a reemergence in oncology therapeutic development. Of the 15 ADCs now approved, 12 received approval by the United States Food and Drug Administration in the last seven years, and over 150 ADCs are presently in clinical development. Accelerated approvals of ADCs reflect a continuing advancement of ideas and techniques that are helping to overcome the challenges faced by first-generation ADCs.
For example, one challenge faced by ADC developers involves balancing a payload’s ability to eradicate cancer cells with an ADC’s stability and tolerability while in the bloodstream or when taken up by healthy cells. A key recent breakthrough has been an improved comprehension of linker chemistry. A new class of linkers that cleave only under conditions found within tumor microenvironments can now minimise off-target effects.
Refined manufacturing processes have also improved ADC’s stability and efficacy. Traditional manufacturing methods utilise bioreactors, which must be cleaned between batches and risk introducing viral and bacterial contamination. In turn, contamination can provoke an immune response to the ADC, reducing its stability in the bloodstream. The sector is now moving away from multi-use bioreactors toward presterilised, disposable, component-based toolsets, which reduce contamination risk while allowing for faster and more flexible production.
The intersection of advances in ADC development brightens the drug class’s future. ADC developers are now combining innovations that optimise ADC’s discrete components — the antibody, the linker, the target, and the payload — to make therapies that are safer, more targeted, and more potent. In addition, developers are experimenting with new methods of ADC manufacturing, administering ADCs earlier in a patient’s treatment pathway, and developing ADCs in combination with other targeted and immunotherapies. With ADCs emerging as one of the fastest-growing segments of pharmaceuticals in 2024, the number of FDA approvals are likely to accelerate, revealing new treatment pathways and new problems to solve along the way.
Learn more about ICON’s services and how we can support your ADC clinical development, please contact us.
This article was first published on Clinical Oncology Daily on 3 June 2024.
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
-
Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Flexible delivery models
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel